Product Description
Mechanisms of Action: FGFR2 Agonist,FGFR3 Agonist
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: TrialSpark
Company Location:
Company CEO:
Additonal Commercial Interests: Merck KGaA
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Fractures, Stress|Knee Injuries|Other|Osteoarthritis|Osteoarthritis, Knee
Phase 1: Osteoarthritis, Knee
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FORWARD | P2 |
Completed |
Osteoarthritis |
2019-05-07 |
|
| FORWARD | P2 |
Completed |
Osteoarthritis, Knee |
2016-05-05 |
|
| EMR700692-007 | P2 |
Terminated |
Fractures, Stress|Knee Injuries |
2013-10-01 |
|
| Phase II Trial of AS902330 as Adjunct to Microfracture in Cartilage Injury | P2 |
Completed |
Other |
2013-09-10 |